BioNxt Solutions (TSE:BNXT) has released an update.
BioNxt Solutions has announced a partnership with a German-based contract research, development, and manufacturing organization to advance their Cladribine oral dissolvable film for Multiple Sclerosis. The collaboration aims to achieve several key milestones, including technology transfer and GMP-certified clinical sample manufacturing. Cladribine, with a market presence in over 75 countries, targets a growing MS drug market projected to reach USD 41 billion by 2033.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.
